B-Cell Activating Factor (BAFF) ELISA Kit
INTENDED USE
Human BAFF ELISA kit is designed to be used for measuring in vitro quantitative concentrations of B-cell activating factor (BAFF) tissue homogenate, serum, plasma and other biological fluids. This assay has a minimum detection limit of 37.5 pg/ml.
BACKGROUND
B-cell activating factor (BAFF) which is also known as APOL-related leukocyte expressed ligand (TALL-1), dendritic cell-derived TNF-like molecule (CD257 antigen) and B Lymphocyte Stimulator (BLyS), is part of the tumor necrosis factor ligand superfamily member 13B proteins. BAFF is a glycoprotein which is 285 amino acid long at it has the ability to undergo glycosylation at residue 124. It is usually expressed as a membrane-bound type II transmembrane protein that is found on a number of different cells such as dendritic cells, bone marrow stromal cells and monocytes.
BAFF is the natural ligand for three tumor necrosis factor receptors which are called BAFF-R (BR3), BCMA, and TACI and cyclophilin ligand interactor), all of these are displaying differing binding affinities for it. Signalling through BAFF-R or BCMA can be used to stimulate B lymphocytes to order to undergo proliferation and to counter apoptosis. Whereas, BCMA displays an intermediate binding phenotype and will work with APRIL and BAFF.
BAFF is a cytokine which is a member of the tumor necrosis factor (TNF) ligand family and is a ligand for receptors TNFRSF13B/TACI, TNFRSF13C/BAFF-R and TNFRSF17/BCMA. It is essentially expressed in B cell lineage cells which can act as a potent B cell activators, it also displays vital roles in B cell proliferation and differentiation. Excessive level of BAFF have be identified to result in abnormally high antibody production which can cause rheumatoid arthritis, systemic lupus erythmatosis and a number of other autoimmune diseases.
BAFF ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- One 96-Well Plate: Pre-coated with anti-BAFF antibody.
- Standards: Concentrations 0, 62.5, 125, 250, 500, 1000, 2000, 4000 pg/ml, made up from lyophilized recombinant human BAFF.
- Sample/Standard Dilution Buffer.
- Biotinylated-labelled BAFF Antibody.
- Antibody Dilution Buffer.
- HRP-Streptavidin Conjugate (SABC).
- SABC Dilution Buffer.
- TMB Substrate.
- Wash Buffer (25x).
- Plate Sealer.
- Product Instructions.
SENSITIVITY
The minimum detection sensitivity level of B-cell activating factor using this human BAFF ELISA kit was 37.5 pg/ml. The dynamic range for this assay is 62.5 – 4,000 pg/ml.
ASSAY CHARACTERISTICS
– B-Cell Activating Factor (BAFF): ELISA
– Specificity: Highly specific for BAFF, no cross reactivity or interference between BAFF and analogues was detected.
– Recovery: Serum (88 – 101%), EDTA Plasma (86 – 105%), Heparin Plasma (89 – 104%).
– Linearity: Serum (86 – 104%), EDTA Plasma (83 – 101%), Heparin Plasma (81 – 86%).
– Precison Intra-Assay: CV < 8%.
– Precison Inter-Assay: CV < 10%.
– Stability: Less than 10%.
REFERENCES
- BAFF and the regulation of B cell survival. Immunol Lett. (2003) 88 (1): 57-62. Review. Schneider P. and Tschopp J.
- Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol. (2011) 73 (1): 1-7. Review. Lied G.A. and Berstad A.
- The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun. (2005) 8: 243-65. Review. Mackay F., et al.
- BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol. (2012) 90 (3): 293-303. Review. Vincent F.B., et al.
- BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. (2011) 317 (9): 1270-7. Review. Liu Z. and Davidson A.
ADDITIONAL INFORMATION
- Full Name: B-Cell Activating Factor (BAFF) ELISA Kit
- Reactivity: Human
- Sample Type: Biological Fluids, Serum, Tissue Homogenates, Plasma
- Sensitivity: 37.5 pg/ml
